Crane LaShonda, Jennings Ashley, Fitzpatrick Megan B, Mukherjee Meghna, Pitchford Callie, Nacht Amy, Mack Nia'Ja, Krueger Kristina, Favreau Jessica, Conway Kristin, Gillis Laura, Conageski Christine, Sutton Elizabeth
Planned Parenthood Gulf Coast, Inc, Houston, Texas, USA.
University of Wisconsin, Madison, Wisconsin, USA.
Womens Health Rep (New Rochelle). 2025 May 19;6(1):564-575. doi: 10.1089/whr.2025.0017. eCollection 2025.
Vaginal self-collection offers an effective option for cervical cancer (CC) screening that can improve screening experiences and engagement.
This article presents data from a multi-center pilot study ( = 185) across the United States, evaluating experiences and preferences reported with an at-home self-collection device compared with clinician-collected screening using a speculum. The device is designed specifically for at-home self-collection and optimized for performance and usability, where collected samples are tested for high-risk human papillomavirus (hrHPV) using the Roche cobas HPV test. In an earlier report, self-collected samples using this device showed high agreement for hrHPV detection when compared with clinician-collection with a speculum and cervical brush.
Participants were screened with a self-collection device and a clinician-collection. They provided feedback about their experiences via usability and preference surveys.
Significantly more participants reported pain ( < 0.001), discomfort ( < 0.001), embarrassment ( < 0.001), and nervousness ( < 0.001) during clinician-collection compared with self-collection. In contrast, being at-ease ( < 0.001) and in-control ( < 0.001) were reported significantly more during self-collection. Similar patterns held across demographic groups relevant to CC screening engagement and related risk (i.e., sexual orientation, menopause status, income, and prior HPV diagnosis). Almost all (94% [156/166]) felt confident using the at-home self-collection device if they knew the results would be equivalent to clinician-collection. The device demonstrated wide usability, with 96% (163/170) successfully self-collecting using only the device's provided instructions.
By improving screening experiences and accessibility, at-home self-collection can increase screening participation and accelerate progress toward eliminating CC as a public health concern in the United States.
阴道自我采样为宫颈癌筛查提供了一种有效的选择,可改善筛查体验和参与度。
本文展示了一项在美国开展的多中心试点研究(n = 185)的数据,评估了与使用窥器由临床医生采集样本进行筛查相比,使用家用自我采样设备的体验和偏好。该设备专为在家自我采样而设计,并在性能和易用性方面进行了优化,采集的样本使用罗氏 cobas HPV 检测法检测高危型人乳头瘤病毒(hrHPV)。在一份早期报告中,与使用窥器和宫颈刷由临床医生采集样本相比,使用该设备自我采集的样本在 hrHPV 检测方面显示出高度一致性。
参与者分别使用自我采样设备和由临床医生采集样本进行筛查。他们通过可用性和偏好调查提供了关于自身体验的反馈。
与自我采样相比,显著更多的参与者报告在临床医生采集样本过程中感到疼痛(P < 0.001)、不适(P < 0.001)、尴尬(P < 0.001)和紧张(P < 0.001)。相比之下,自我采样过程中报告感到自在(P < 0.001)和能掌控(P < 0.001)的参与者显著更多。在与宫颈癌筛查参与度及相关风险相关的人口统计学分组(即性取向、绝经状态、收入和既往 HPV 诊断情况)中,均呈现类似模式。几乎所有(94% [156/166])参与者表示,如果他们知道结果与临床医生采集样本相当,就会对使用家用自我采样设备充满信心。该设备显示出广泛的易用性,96%(163/170)的参与者仅根据设备提供的说明就成功进行了自我采样。
通过改善筛查体验和可及性,在家自我采样可提高筛查参与率,并加速在美国消除宫颈癌这一公共卫生问题的进程。